Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


June 29, 2007
Designer Enzyme to Fight HIV Shows Promise
Scientists in Germany have constructed a custom enzyme that reverses the process by which HIV inserts its genetic material into a CD4 cell's DNA, suggesting that treatment with similar enzymes could potentially rid infected cells of the virus.
June 26, 2007
Treatment Improves Survival Among IDUs
Survival among HIV-infected intravenous drug users (IDUs) has improved dramatically since the introduction of combination antiretroviral therapy, with survival rates similar to HIV-negative IDUs.
June 25, 2007
Dietary Supplement Rule Announced, Questioned
The FDA has announced plans to ensure the quality of dietary supplements. But does the new rule go far enough?
June 22, 2007
Drug-Resistant HIV in Semen Stirs Concerns
Drug-resistant HIV can remain detectable in the male genital tract for an extended period of time, and potentially prolong the risk to sexual partners, according to a study published in the August 1 issue of the Journal of Infectious Disease.
June 21, 2007
Hep B and HIV Baraclude Users Beware
Treating hepatitis B patients with the drug Baraclude® (entecavir) can cause those who are also infected with HIV to become resistant to two vital HIV drugs, according to a new report in the New England Journal of Medicine.
Panacos' Bevirimat Back on Track
Panacos Pharmaceuticals reports that it is back on track with the development of its maturation inhibitor bevirimat (PA-457), after hitting a dosing snag reported in December 2006.
June 20, 2007
Maraviroc: Approvable, but not yet Approved
Pfizer has learned from the FDA that its entry inhibitor maraviroc is "approvable," but not yet approved.
June 19, 2007
Reyataz May Cause Kidney Stones
The FDA has received 30 reports of kidney stones among HIV-positive patients being treated with Reyataz, prompting the company to update the drug's package insert.
Death Rates Higher Among Rural Positive Patients - But Why?
A new study confirms that HIV-positive people residing in rural areas of the U.S. are more likely to die than those who live in urban areas. Unfortunately, few explanations for this disparity were apparent to the researchers.
June 15, 2007
Several Factors Raise Women's Bone Loss Risk
Decreased bone mineral density (BMD) is both highly prevalent and severe among underweight women with HIV and is associated with other factors like menstrual irregularities, reduced testosterone levels, lower lean body mass, and white race.
June 14, 2007
Racially and Gender Diverse Aptivus Study Underway
Researchers are now enrolling patients into its SPRING clinical trial, one of the largest racially and gender diverse international studies of highly treatment-experienced HIV-positive patients.
June 12, 2007
LDL Drops with Sustiva to Viramune Switch
HIV-positive people taking Sustiva may be able to lower their levels of bad cholesterol by switching to Viramune (nevirapine).
June 08, 2007
People with HIV May Need Longer TB Treatment
HIV-positive people with active TB are more likely to experience a relapse of the disease after receiving the same treatment typically used to treat HIV-negative TB patients.
June 07, 2007
Roche's Viracept Recalled; Pfizer's U.S. Version Okay
Roche, the manufacturer of Viracept (nelfinavir) in all countries other than the U.S., Canada, and Japan, has recalled the drug. Pfizer's version used in the U.S. is okay.
June 06, 2007
New Drugs Possible from Discovered HIV Transport System
Likening HIV to “hobos on a train,” researchers at Johns Hopkins University School of Medicine have found that the virus uses a pre-existing transport system to leave one infected CD4 cell and move on to infect news ones.
June 05, 2007
Early Treatment may have CD4 Advantage
The chances of achieving and maintaining a CD4 count of 800 or higher are best among those who start antiretroviral therapy early, according to new data from the ATHENA cohort study.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ



Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.